Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,561
  • Shares Outstanding, K 23,785
  • Annual Sales, $ 1,740 K
  • Annual Income, $ -41,850 K
  • 60-Month Beta 1.27
  • Price/Sales 102.52
  • Price/Cash Flow N/A
  • Price/Book 8.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.23
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.41
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +62.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.66 +22.82%
on 09/04/20
9.67 -15.41%
on 08/26/20
-0.42 (-4.88%)
since 08/25/20
3-Month
6.66 +22.82%
on 09/04/20
11.94 -31.49%
on 08/03/20
-1.09 (-11.76%)
since 06/25/20
52-Week
2.05 +299.02%
on 03/19/20
15.00 -45.47%
on 06/18/20
+4.10 (+100.49%)
since 09/25/19

Most Recent Stories

More News
Alpine Immune Sciences to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the...

MHMNF : 54.5000 (unch)
ALPN : 8.18 (+9.07%)
Alpine Immune Sciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the...

ALPN : 8.18 (+9.07%)
New Strong Sell Stocks for September 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

JBLU : 11.53 (+2.04%)
ADVM : 10.81 (+2.95%)
KDMN : 3.80 (+0.26%)
ALPN : 8.18 (+9.07%)
PRVB : 12.19 (+2.96%)
Alpine Immune Sciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

--- Received $60 million upfront cash payment from AbbVie; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones -

ALPN : 8.18 (+9.07%)
Alpine Immune Sciences to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the...

ALPN : 8.18 (+9.07%)
Alpine Immune Sciences to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the...

ALPN : 8.18 (+9.07%)
Alpine Begins Dosing in Phase I Study for Advanced Malignancies

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

ABBV : 86.23 (+0.37%)
ALDX : 6.83 (+0.89%)
ALPN : 8.18 (+9.07%)
ATXI : 10.92 (+0.09%)
Translate Bio Up on Vaccine Agreement Expansion With Sanofi

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

SNY : 50.78 (-0.02%)
TBIO : 13.13 (+3.88%)
BLCM : 6.51 (+2.68%)
ALPN : 8.18 (+9.07%)
Alpine Immune Sciences Announces First Patient Dosed in NEON-1 Phase 1 Trial of ALPN-202 in Patients with Advanced Malignancies

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that...

ALPN : 8.18 (+9.07%)
Thinking about buying stock in Microvision, InVitae Corp, Alpine Immune Sciences, Anavex Life Sciences, or Ford Motor?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, NVTA, ALPN, AVXL, and F.

ALPN : 8.18 (+9.07%)
AVXL : 3.87 (unch)
F : 6.51 (-2.25%)
NVTA : 44.67 (+4.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ALPN with:

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

2nd Resistance Point 8.69
1st Resistance Point 8.44
Last Price 8.18
1st Support Level 7.76
2nd Support Level 7.33

See More

52-Week High 15.00
Fibonacci 61.8% 10.05
Fibonacci 50% 8.52
Last Price 8.18
Fibonacci 38.2% 7.00
52-Week Low 2.05

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar